 DUBLIN, Ireland, Feb. 01, 2021 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA today announced that following further analyses by the Company and multiple in-depth discussions with the U.S. Food and Drug Administration FDA regarding the previous analysis of patients categorized as Mayo Stage IV at baseline in the VITAL study, Prothena is advancing birtamimab into the confirmatory Phase 3 AFFIRM-AL study in this category of patients with AL amyloidosis. This registration-enabling study will be conducted with a primary endpoint of all-cause mortality at p 